WHO approves Bavarian Nordic’s mpox vaccine for adolescents

The World Health Organisation (WHO) said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct 8.

The WHO declared mpox a global public health emergency for the second time in two years in August after a new type of the virus spread from...